Wanbury gets Certificate of Suitability for cough relief medicine in Europe
Maharashtra: Wanbury Limited has announced that it has been awarded a Certificate of Suitability (CEP) by the European Directorate for the Quality of Medicines (EDQM) for its Dextromethorphan active pharmaceutical ingredient (API), antitussive (cough) medicine.
Wanbury Limited has a presence in API global market and domestic branded Formulation. Wanbury strength lies in Active Pharmaceutical Ingredient (API) Sales & Marketing in over 50 countries and Pan-India Formulation presence. The Company has a basket of over 13 API products. It has the larger customer base in Europe & US for Tramadol & Setraline (API).The Company has two US-FDA approved multi-product API facilities and one plant under operation for semi-regulated markets. It has pan-India presence in ethical formulations with a portfolio of close to 70 brands.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.